These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 4191303)

  • 1. Considerations on the sensitization properties of Bordetella pertussis.
    Kirchev P; Vesselinova H; Boshkov B; Galabov S
    Nauchni Tr Vissh Med Inst Sofiia; 1969; 48(1):59-63. PubMed ID: 4191303
    [No Abstract]   [Full Text] [Related]  

  • 2. Action of vaccinia virus on the reactivity of albino mice inoculated with pertussis vaccine.
    Pozsgi N; David C; Andreescu V; Caffé I; Ghyka G
    Z Immunitatsforsch Exp Klin Immunol; 1971 Aug; 142(2):129-35. PubMed ID: 4105636
    [No Abstract]   [Full Text] [Related]  

  • 3. The reactivity of mice after hyperimmunization with Bordetella pertussis.
    David C; Pozsgi N; Andreescu V; Caffé I
    Arch Roum Pathol Exp Microbiol; 1974; 33(3-4):313-8. PubMed ID: 4377531
    [No Abstract]   [Full Text] [Related]  

  • 4. Whole-cell pertussis vaccine protects against Bordetella pertussis exacerbation of allergic asthma.
    Ennis DP; Cassidy JP; Mahon BP
    Immunol Lett; 2005 Feb; 97(1):91-100. PubMed ID: 15626480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypersensitivity in mice. II. The effect of chemical compounds on systemic active anaphylaxis and on anaphylaxis-like reactions in normal and B. pertussis-pretreated mice.
    Dietrich FM; Komarek A; Pericin C
    Int Arch Allergy Appl Immunol; 1971; 40(4-5):495-506. PubMed ID: 4102842
    [No Abstract]   [Full Text] [Related]  

  • 6. [Bordetella pertussis spheroplasts. 4. The protective, histamine-sensitizing and toxic action of spheroplasts and spheroplast cell walls].
    Milleck J; Ocklitz HW
    Zentralbl Bakteriol Orig A; 1972 Mar; 219(3):358-65. PubMed ID: 4122376
    [No Abstract]   [Full Text] [Related]  

  • 7. The soluble protective antigen and the histamine-sensitizing factor of Bordetella pertussis.
    Pieroni RE; Broderick EJ; Levine L
    J Immunol; 1965 Oct; 95(4):643-50. PubMed ID: 4284676
    [No Abstract]   [Full Text] [Related]  

  • 8. [Immunogenic value of the diphtheria-tetanus-pertussis trivaccine depending on the quantitative variations of its antigenic components. IV. Immunogenic properties of the pertussis compound].
    Andreescu V; Caffé I; Marion M; Pozsgi N; Stănică E; Stoian C; Kranzdorf H
    Arch Roum Pathol Exp Microbiol; 1970 Sep; 29(3):487-92. PubMed ID: 4328575
    [No Abstract]   [Full Text] [Related]  

  • 9. [Immunobiological properties of Bordetella pertussis].
    Kopacka B
    Pediatr Pol; 1972; 47(3):361-70. PubMed ID: 4336329
    [No Abstract]   [Full Text] [Related]  

  • 10. Prevention of pertussis among adolescents by vaccination: taking action on what we know and acknowledging what we do not know.
    Wharton M
    Clin Infect Dis; 2004 Jul; 39(1):29-30. PubMed ID: 15206049
    [No Abstract]   [Full Text] [Related]  

  • 11. Variation in Bordetella pertussis.
    Cameron J
    J Pathol Bacteriol; 1967 Oct; 94(2):367-74. PubMed ID: 4294462
    [No Abstract]   [Full Text] [Related]  

  • 12. Lung pathology and immediate hypersensitivity in a mouse model after vaccination with pertussis vaccines and challenge with Bordetella pertussis.
    Vandebriel RJ; Gremmer ER; Vermeulen JP; Hellwig SM; Dormans JA; Roholl PJ; Mooi FR
    Vaccine; 2007 Mar; 25(12):2346-60. PubMed ID: 17224216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antigens of Bordetella pertussis and their repercussion in immunization programs against whooping cough].
    Casal Lombos J
    Rev Sanid Hig Publica (Madr); 1971 May; 45(5):575-87. PubMed ID: 4330706
    [No Abstract]   [Full Text] [Related]  

  • 14. The relevance of agglutinogenic types of Bordetella pertussis in the assay of pertussis vaccines.
    Cameron J
    Prog Immunobiol Stand; 1967; 3():302-8. PubMed ID: 4314430
    [No Abstract]   [Full Text] [Related]  

  • 15. [Correlation between laboratory evaluation of vaccines in animals and reactions to vaccination and serologic response in children vaccinated against pertussis].
    Adonajlo A; Andrzejczak-Kardymowicz B
    Przegl Epidemiol; 1973; 27(2):183-95. PubMed ID: 4352704
    [No Abstract]   [Full Text] [Related]  

  • 16. Pertussis antigens--screening models on toxicity.
    Ronneberger H; Blackkolb F; Guthöhrlein G
    Arch Toxicol Suppl; 1982; 5():129-32. PubMed ID: 6285854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Serologic controls of anti-pertussis vaccination].
    Mynard MC; Aymé G; Triau R
    Rev Immunol Ther Antimicrob; 1969; 33(1):7-20. PubMed ID: 4181401
    [No Abstract]   [Full Text] [Related]  

  • 18. [Demonstration of the immunostimulating component(s) in Bordetella pertussis (Phase I, strain Tohama), other than cell wall peptidoglycan, endotoxic lipopolysaccharide and pertussis toxin].
    Kubo T
    Osaka Daigaku Shigaku Zasshi; 1984 Jun; 29(1):138-57. PubMed ID: 6088743
    [No Abstract]   [Full Text] [Related]  

  • 19. Time relationships between injection of antigen and adjuvant. II. Immunosuppression induced by Bordetella pertussis vaccine when given before secondary antigenic stimulation.
    Finger H; Bartoschek M; Emmerling P
    Pathol Microbiol (Basel); 1972; 38(2):93-102. PubMed ID: 4337644
    [No Abstract]   [Full Text] [Related]  

  • 20. [Study of the immunity state in the potency test of pertussis vaccine by mouse intracerebral method].
    Ishihara S
    Nihon Saikingaku Zasshi; 1966 Feb; 21(2):81-7. PubMed ID: 4289110
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.